![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Global X China Biotech Innovations ETF | NASDAQ:CHB | NASDAQ | Exchange Traded Fund |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.64 | 2.67 | 10.66 | 0 | 01:00:00 |
RNS Number:5985N UBS Limited 16 July 2003 Date of disclosure...16 July 2003 DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) AND 8.3 OF THE CITY CODE ON TAKEOVERS AND MERGERS Date of dealing ...15 July 2003 Dealing in ... Chubb plc ......................................(name of company) (1) Class of securities (eg ordinary shares) ........................ORD 36p (2) Amount bought Amount sold Price per unit 40,000,000 76.0p (3) Resultant total of the same class owned or controlled (and percentage of class) ( %) 83,070,990 (10.02%) (4) Party making disclosure ... UBS Limited (5) EITHER (a) Name of purchaser/vendor (Note 1) ...Ceesail Limited OR (b) If dealing for discretionary client(s), name of fund management organisation (6) Reason for disclosure (Note 2) (a) associate of (i) offeror (Note 3) YES (ii) offeree company NO Specify which category or categories of associate (1-8 overleaf) 1 If category (8), explain (b) Rule 8.3 (ie disclosure because of ownership or control of 1% or more of the class of relevant securities dealt in) NO Signed, for and on behalf of the party named in (4) above .......... n/a (Also print name of signatory) ........................Philip Ellick Telephone and extension number ........................020 7568 4161 ______________________________________ Note 1. Specify owner, not nominee or vehicle company. If relevant, also identify controller of owner, eg where an owner normally acts on instructions of a controller. Note 2. Disclosure might be made for more than one reason; if so, state all reasons. Note 3. Specify which offeror if there is more than one. Note 4. When an arrangement exists with any offeror, with the offeree company or with an associate of any offeror or of the offeree company in relation to relevant securities, details of such arrangement must be disclosed, as required by Note 6 on Rule 8. Note 5. It may be necessary, particularly when disclosing derivative transactions, to append a sheet to this disclosure form so that all relevant information can be given. Note 6. In the case of an average price bargain, each underlying trade should be disclosed. For full details of disclosure requirements, see Rule 8 of the Code. If in doubt, contact the Panel on Takeovers and Mergers, Monitoring Section, Tel. No: 020 7638 0129. This information is provided by RNS The company news service from the London Stock Exchange END DCCEAPXSFSLDEFE
1 Year Global X China Biotech I... Chart |
1 Month Global X China Biotech I... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions